Answers are grounded in this paper and cite their sources.
Background The impact of clonal haematopoiesis of indeterminate potential (CHIP), a novel cardiovascular risk factor, remains unclear in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), where cardiovascular disease (CVD) is the main cause of mortality. Methods We analysed data from 140,086 UK Biobank participants with MASLD. CHIP was identified via whole-exome sequencing. Incident CVD, including coronary heart disease (CHD), stroke, and heart failure (HF), was the primary outcome. Cox proportional hazards models assessed the association between CHIP and CVD risk. Results During a median 13.5-year follow-up, 15.7% of participants developed CVD. CHIP was associated with a higher risk of CVD (HR: 1.16, 95% CI: 1.09–1.23), with higher risks of stroke (HR: 1.22, 95% CI: 1.07–1.38) and HF (HR: 1.34, 95% CI: 1.21–1.49). Mutations in ASXL1, SRSF2, JAK2 , and SF3B1 were associated with a particularly high CVD risk. Additionally, a higher clonal haematopoiesis risk score (CHRS) was associated with incident CVD, CHD, stroke, and HF. In the three-category analysis, the P value for trend was significant for all outcomes, but the association was confined to large CHIP for CVD and CHD, whereas both CHIP categories showed elevated estimates for stroke and HF. Conclusions CHIP is independently associated with incident CVD in patients with MASLD. These findings support prospective evaluation of CHIP-informed cardiovascular risk stratification in this population.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: